CTLA4 and Marinesco-Sjogren syndrome: For both CMS3 and CMS4 patients in MSS, higher SDHA expression was associated with better treatment outcomes, indicating that SDHA might become a new biomarker for predicting the outcomes of immune checkpoint blockades such as anti-PD-1/PD-L1 and anti-CTLA-4.